康恩贝：子公司TFA003片获得药物临床试验批准通知书

Core Viewpoint - The company announced that its wholly-owned subsidiary, Hangzhou Kangnbei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, which are aimed at treating diabetic nephropathy [1] Group 1 - The clinical trial approval is for TFA003 tablets, which are classified as traditional Chinese medicine under categories 2.1 and 2.3 [1] - The administration route for TFA003 is oral, and the optimal dosage will be confirmed after the completion of clinical trials [1] - Preliminary pharmacological and pharmacokinetic animal studies indicate that TFA003 has significant therapeutic effects on diabetic nephropathy, improving renal function indicators in urine and blood, as well as enhancing glomerular filtration and tubular reabsorption functions [1] Group 2 - The company has invested approximately RMB 29.57 million in the research and development of TFA003 to date [1] - The drug shows potential for development as a new traditional Chinese medicine for diabetic nephropathy based on its efficacy and safety profile demonstrated in preclinical studies [1]